Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 35, Issue 13, 2017, Pages 1395-1402

  Dess, Robert T ^a   Sun, Yilun ^a   Matuszak, Martha M ^a   Sun, Grace ^a   Soni, Payal D ^a   Bazzi, Latifa ^a   Murthy, Venkatesh L ^a   Hearn, Jason W D ^a   Kong, Feng Ming ^b   Kalemkerian, Gregory P ^a   Hayman, James A ^a   Ten Haken, Randall K ^a   Lawrence, Theodore S ^a   Schipper, Matthew J ^a   Jolly, Shruti ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART ARREST; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROIMAGING; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERICARDITIS; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; STEREOTACTIC BODY RADIATION THERAPY; X-RAY COMPUTED TOMOGRAPHY; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOTOXICITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY;

EID: 85018346472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.6142     Document Type: Article

References (32)

1. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744-2753, 1980
2. Aupérin A, Le Péchoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181-2190, 2010
3. Machtay M, Bae K, Movsas B, et al: Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 82:425-434, 2012
4. Martel MK, Ten Haken RK, Hazuka MB, et al: Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 24:31-37, 1999
5. Bradley JD, Moughan J, Graham MV, et al: A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: Phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 77:367-372, 2010
6. Stinchcombe TE, Lee CB, Moore DT, et al: Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 3:1279-1285, 2008
7. Socinski MA, Blackstock AW, Bogart JA, et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and doseescalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
8. Bradley JD, Paulus R, Komaki R, et al: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187-199, 2015
9. Faivre-Finn C: Dose escalation in lung cancer: Have we gone full circle? Lancet Oncol 16:125-127, 2015
10. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013
11. Darby SC, McGale P, Taylor CW, et al: Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557-565, 2005
12. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
13. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11: 1208-1215, 1993
14. RTOG Foundation, Clinical Trials, Protocol Table, Study Details: RTOG 1106/ACRIN 6697, Randomized phase II trial of individualized adaptive radiotherapy using during treatment FDG-PET/CT and modern technology in locally advanced non-small lung cancer (NSCLC). 2016
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. Taylor CW, Nisbet A, McGale P, et al: Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 69:1484-1495, 2007
17. Gillette EL, McChesney SL, Hoopes PJ: Isoeffect curves for radiation-induced cardiomyopathy in the dog. Int J Radiat Oncol Biol Phys 11:2091-2097, 1985
18. Stewart JR, Fajardo LF, Gillette SM, et al: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205-1211, 1995
19. Cosset JM, Henry-Amar M, Girinski T, et al: Late toxicity of radiotherapy in Hodgkin's disease: The role of fraction size. Acta Oncol 27:123-129, 1988
20. Feng M, Moran JM, Koelling T, et al: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10-18, 2011
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
22. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 21:105-113, 1998
23. Stone NJ, Robinson JG, Lichtenstein AH, et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889-2934, 2014
24. Speirs CK, DeWees TA, Rehman S, et al: Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol 12:293-301, 2017
25. Wang K, Eblan MJ, Zagar TM, et al: Cardiac toxicity after radiation for stage III non-small cell lung cancer: Pooled analysis of several prospective doseescalation trials delivering 70 to 90 Gy. Int J Radiat Oncol Biol Phys 96:S130, 2016
26. Chun SG, Hu C, Choy H, et al: Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 35:56-62, 2017
27. Chang JY, Zhang X, Wang X, et al: Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65:1087-1096, 2006
28. Marks LB, Zagar TM, Kaidar-Person O: Reassessing the time course for radiation-induced cardiac mortality in patients with breast cancer. Int J Radiat Oncol Biol Phys 97:303-305, 2017
29. Marks LB, Yu X, Prosnitz RG, et al: The incidence and functional consequences of RTassociated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63:214-223, 2005
30. Ramroth J, Cutter DJ, Darby SC, et al: Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: Meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 96: 736-747, 2016
31. Schultz-Hector S, Sund M, Thames HD: Fractionation response and repair kinetics of radiation-induced heart failure in the rat. Radiother Oncol 23:33-40, 1992
32. Gomez DR, Yusuf SW, Munsell MF, et al: Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with highdose heart exposure. J Thorac Oncol 9:1554-1560, 2014